The concentration of knowledge of new targets in smaller biotech companies can also be seen with
the IL1RAP-targeting antibody nadunolimab (CAN04) being developed by Cantargia (STO: CANTA;
note CANTA is a client of Edison Investment Research) for the treatment of TNBC. Cantargia is
leveraging its knowledge of the IL1RAP pathway to develop nadunolimab in various oncology
indications, for which the company believes the drug will limit tumor growth and stimulate an
immune response to the cancer. A Phase Ib/2 trial (NCT05181462) investigating nadunolimab in
combination with carboplatin and gemcitabine for the treatment of TNBC is currently recruiting
patients.


https://www.youtube.com/watch?v=q_pD9kukd0Q

Canta har gått over 45 prosent på to dager.

https://www.marketscreener.com/quote/stock/CANTARGIA-AB-PUBL-31837413/

+120%

+25% idag.

Cantargia Up 40% After Completing Toxicity Study For Anti-inflammatory Drug


https://www.marketscreener.com/quote/stock/CANTARGIA-AB-PUBL-31837413/

ser litt på denne, er det lurt å invistere?